Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
When a blood clot (thrombus) breaks and travels in the blood, it is known as a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery.
The Thromboembolism drugs in development market research report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.
What are the key targets in the Thromboembolism pipeline products market?
The key targets in the Thromboembolism pipeline products market are Coagulation Factor X, Coagulation Factor XI, Prothrombin, Antithrombin III, Plasminogen, Alpha 2 Antiplasmin, Coagulation Factor V, P Selectin Glycoprotein Ligand 1, P2Y Purinoceptor 12 ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Plasminogen Activator Inhibitor 1, and others.
Thromboembolism Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the Thromboembolism pipeline products market?
The key mechanisms of action in the Thromboembolism pipeline products market are Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Prothrombin Inhibitor, Antithrombin III Activator, Plasminogen Activator, Alpha 2 Antiplasmin Inhibitor, Coagulation Factor V Inhibitor, P Selectin Glycoprotein Ligand 1 Inhibitor, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2YAntagonist, Plasminogen Activator Inhibitor 1 Inhibitor, and others.
Thromboembolism Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the Thromboembolism pipeline products market?
The key routes of administration in the Thromboembolism pipeline products market are oral, intravenous, subcutaneous, intramuscular, intravenous bolus, topical, and transdermal.
Thromboembolism Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the Thromboembolism pipeline products market?
The different molecule types in the Thromboembolism pipeline products market are small molecule, monoclonal antibody, recombinant enzyme, polysaccharide, antisense oligonucleotide, blood derivative, fusion protein, peptide, and recombinant protein.
Thromboembolism Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Which are the major companies in the Thromboembolism pipeline products market?
Some of the major companies in the Thromboembolism pipeline products market are Bristol-Myers Squibb Co, Alexion Pharmaceuticals Inc, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Acticor Biotech SAS, Alfasigma SpA, Anthos Therapeutics Inc, Bio-Synectics Inc, Boehringer Ingelheim International GmbH, and China Biologic Products Holdings Inc.
Thromboembolism Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Scope
| Key targets | Coagulation Factor X, Coagulation Factor XI, Prothrombin, Antithrombin III, Plasminogen, Alpha 2 Antiplasmin, Coagulation Factor V, P Selectin Glycoprotein Ligand 1, P2Y Purinoceptor 12 ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Plasminogen Activator Inhibitor 1, and Others |
| Key mechanism of action | Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Prothrombin Inhibitor, Antithrombin III Activator, Plasminogen Activator, Alpha 2 Antiplasmin Inhibitor, Coagulation Factor V Inhibitor, P Selectin Glycoprotein Ligand 1 Inhibitor, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2YAntagonist, Plasminogen Activator Inhibitor 1 Inhibitor, and Others |
| Key routes of administration | Oral, Intravenous, Subcutaneous, Intramuscular, Intravenous Bolus, Topical, and Transdermal |
| Molecule type | Small Molecule, Monoclonal Antibody, Recombinant Enzyme, Polysaccharide, Antisense Oligonucleotide, Blood Derivative, Fusion Protein, Peptide, and Recombinant Protein |
| Major companies | Bristol-Myers Squibb Co, Alexion Pharmaceuticals Inc, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Acticor Biotech SAS, Alfasigma SpA, Anthos Therapeutics Inc, Bio-Synectics Inc, Boehringer Ingelheim International GmbH, and China Biologic Products Holdings Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alexion Pharmaceuticals Inc
Alfasigma SpA
Anthos Therapeutics Inc
Bayer AG
Bio-Synectics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
China Biologic Products Holdings Inc
China Resources Emde Biological Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
Espero BioPharma Inc
EVAS Therapeutics LLC
GC Pharma
Indiana Lysis Technologies LLC
Ionis Pharmaceuticals Inc
IPCA Laboratories Ltd
Jiangsu Hengrui Medicine Co Ltd
KLUS Pharma Inc
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Ono Pharmaceutical Co Ltd
PharmaDiall
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tetherex Pharmaceuticals Corp
Tianjin Pharmaceuticals Group Co Ltd
Translational Sciences Inc
Verseon Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Thromboembolism pipeline products market?
The key targets in the Thromboembolism pipeline products market are Coagulation Factor X, Coagulation Factor XI, Prothrombin, Antithrombin III, Plasminogen, Alpha 2 Antiplasmin, Coagulation Factor V, P Selectin Glycoprotein Ligand 1, P2Y Purinoceptor 12 ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, Plasminogen Activator Inhibitor 1, and others.
-
What are the key mechanisms of action in the Thromboembolism pipeline products market?
The key mechanisms of action in the Thromboembolism pipeline products market are Coagulation Factor X Inhibitor, Coagulation Factor XI Inhibitor, Prothrombin Inhibitor, Antithrombin III Activator, Plasminogen Activator, Alpha 2 Antiplasmin Inhibitor, Coagulation Factor V Inhibitor, P Selectin Glycoprotein Ligand 1 Inhibitor, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2YAntagonist, Plasminogen Activator Inhibitor 1 Inhibitor, and others.
-
What are the key routes of administration in the Thromboembolism pipeline products market?
The key routes of administration in the Thromboembolism pipeline products market are oral, intravenous, subcutaneous, intramuscular, intravenous bolus, topical, and transdermal.
-
What are the different molecule types in the Thromboembolism pipeline products market?
The different molecule types in the Thromboembolism pipeline products market are small molecule, monoclonal antibody, recombinant enzyme, polysaccharide, antisense oligonucleotide, blood derivative, fusion protein, peptide, and recombinant protein.
-
Which are the major companies in the Thromboembolism pipeline products market?
Some of the major companies in the Thromboembolism pipeline products market are Bristol-Myers Squibb Co, Alexion Pharmaceuticals Inc, Bayer AG, Jiangsu Hengrui Medicine Co Ltd, Acticor Biotech SAS, Alfasigma SpA, Anthos Therapeutics Inc, Bio-Synectics Inc, Boehringer Ingelheim International GmbH, and China Biologic Products Holdings Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Cardiovascular reports